ANALYSISA four-branch surveillance study in children found 2024 Mycoplasma pneumoniae incidence of 546 per 100,000, and genome sequencing showed four new subclades had replaced older lineages by mid-2024.
3 min read
ANALYSISA Valencia hospital reviewed 108 patients with Candidozyma auris candidemia over eight years. Metastatic infection occurred in 22 percent and roughly doubled the risk of death at 60 and 90 days.
3 min read
WHAT THE STUDY ACTUALLY SAYSThe CENTERSTONE trial found a single dose lowered lab-confirmed spread to household contacts by about a third, but spread that made contacts ill was not significantly cut, and resistant virus emerged in some patients.
3 min read
WHAT THE STUDY ACTUALLY SAYSAgainst 304 carbapenem-resistant A. baumannii isolates from six countries, the experimental drug zosurabalpin kept low MICs — including against metallo-beta-lactamase producers. This is laboratory data, not a cure.
3 min read
WHAT THE STUDY ACTUALLY SAYSA bird-flu virus from British Columbia poultry carried the H275Y mutation that blunts Tamiflu and peramivir. In the lab it stayed vulnerable to zanamivir and baloxavir — and was less virulent in mice.
3 min read
A Manaus trial found chloroquine alone let 27% of Plasmodium vivax patients relapse by day 42; dihydroartemisinin-piperaquine cut that to 2.4%. Paired with primaquine, both drugs did well.
4 min read
Across 41 hospitals in 19 Asian countries, ACORN-HAI found 73.7% of severe bloodstream and ventilator infections were drug-resistant, and 37.7% of those patients died within 28 days.
3 min read
WHAT THE STUDY ACTUALLY SAYSA GBD analysis linked 0.84 million under-five deaths in 2021 to antimicrobial resistance, and directly attributed 0.19 million — declining since 1990 but heaviest in sub-Saharan Africa.
3 min read
A cluster-randomised trial in Saponé found seasonal chemoprevention given to children up to age 10 nearly halved parasite carriage in 5-to-9-year-olds, though supervised delivery brought no clear gain under age five.
3 min read
The AVENIR trial met its resistance endpoint in the gut but not the nose: giving the antibiotic to under-fives lifted macrolide resistance 16% above placebo communities.
3 min read
ANALYSISIn a controlled human infection trial, high-dose mosnodenvir suppressed DENV-3 far below placebo. Resistance-associated changes appeared in every sequenced recipient and none of the placebo group.
4 min read